CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
|
|
- Molly Mitchell
- 5 years ago
- Views:
Transcription
1 CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference on Cardiovascular Health and Diseases in Women and she has served on the national board of the American Heart Association (AHA). In 1998 she received the AHA Physician of the Year Award. She is professor of medicine (Division of Cardiology) at the Emory University School of Medicine and Chief of Cardiology at Grady Memorial Hospital. The Advanced Studies in Medicine (ASiM) senior contributing editor for this issue interviewed Dr Wenger about coronary heart disease and its diagnosis and management in postmenopausal women. ASiM: Current studies indicate that coronary heart disease (CHD) is significantly underdiagnosed in postmenopausal women. What has been your experience with CHD in women? Dr Wenger: CHD is the leading cause of death for US women. 1 However, survey data indicate that 4 of 5 US women and 1 of 3 primary care physicians are not aware of women s vulnerability to CHD. As a result, women and their physicians often fail to relate chest pain to CHD, and another cause is frequently sought. Complaints of chest pain are not as appropriately or aggressively evaluated as they are in men, and women are more likely than men to delay seeking attention for the severe chest pain of myocardial infarction (MI) after the onset of symptoms. Physicians caring for women must evaluate patient complaints of chest pain, particularly when the pain is precipitated by exertion or emotion, and must undertake diagnostic procedures for recognition and risk stratification. These are typically exercise-based tests with or without radionuclide or echocardiographic imaging. ASiM: How do coronary risk factors for postmenopausal women compare with those of the general population? Dr Wenger: Menopausal women have the same coronary risk factors as premenopausal women and the general population. The only aspect that may differ for these women relates to menopausal status, and this has not been shown unequivocally to be a specific risk factor for cardiovascular disease. Coronary risk factors predominate and cluster in older women; thus, this high prevalence of risk factors and menopausal status occur concomitantly as women age. ASiM: Why is primary prevention of CHD such an important issue for postmenopausal women? Dr Wenger: Coronary risk factors are more common in women after menopause. While men are more likely to develop hypertension during middle age 40 to 60 years old women are more likely to develop hypertension at older ages. In addition, isolated systolic hypertension is more prominent among elderly women than elderly men. Diabetes is more common in older women than older men, with the older women far more likely to develop de novo diabetes. Finally, low-density lipoprotein cholesterol levels in women increase after middle age, more so than in men of the same age. ASiM: In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, raloxifene was shown to be beneficial in the prevention of osteoporosis, and outcome measures indicated that an early increase in cardiovascular events was not seen in the patients taking raloxifene. How can clinicians use this information in treating postmenopausal patients? Dr Wenger: The MORE trial evaluated the effect of raloxifene, a selective estrogen receptor modulator, in women at risk for osteoporosis. These women were not selected as being either at risk for breast cancer or at risk for cardiovascular disease. The MORE trial showed that raloxifene is beneficial in the prevention of osteoporosis, in improving bone density, and in the treatment of osteoporotic fractures. 2 For physicians treating menopausal women, this means that estrogen is not the only option for the prevention of osteoporosis; raloxifene, as well as the bisphosphonates, can be considered. (Reprint of MORE trial article can be found on page 721.) Advanced Studies in Medicine 709
2 ASiM: Results of the MORE trial showed no evidence of early increased risk for cardiovascular events. In your opinion, how should that be interpreted by clinicians? Dr Wenger: While raloxifene therapy did not significantly affect the risk for cardiovascular events in the overall cohort, which was comprised of women who were not at increased cardiovascular risk, raloxifene therapy did significantly reduce the risk for cardiovascular events in the subset of women at increased risk based on the Raloxifene Use for the Heart (RUTH) score. This is a post hoc analysis and justifies a clinical trial, which is currently in progress. 2 Whether raloxifene affects the risk for cardiovascular events in postmenopausal women with documented coronary disease or at increased risk for its occurrence is currently being tested prospectively in the RUTH trial, although results will not be available for several years. The primary objectives of RUTH are to determine whether raloxifene at a dosage of 60 mg daily lowers the risk for coronary events, such as coronary death, nonfatal myocardial infarction, or hospitalized acute coronary syndrome other than myocardial infarction, and whether it reduces the risk for developing invasive breast cancer in postmenopausal women at risk for a major coronary event. 3 The suggestive data from the MORE trial should not be construed to document that raloxifene provides cardiovascular protection or protection from breast cancer. As noted, the issue of cardiovascular protection and breast cancer risk reduction is being evaluated in the randomized placebo-controlled RUTH trial, 3 and the comparison of raloxifene with tamoxifen in women at increased risk for breast cancer is being studied in the Study of Tamoxifen and Raloxifene (STAR) trial, which is still enrolling patients at this time. ASiM: Hormone replacement therapy (HRT) was once thought to potentially reduce CHD risk in postmenopausal women. However, recently published reports of current clinical trials indicate that HRT is no longer considered appropriate for primary prevention of cardiovascular disease. One of these trials was part of the Women s Health Initiative (WHI). Can you provide some information on this study? Dr Wenger: The WHI, the largest study of menopausal women ever undertaken, was developed specifically for better understanding of women s health issues, including an improved understanding of cardiovascular disease (CVD) in postmenopausal women. WHI was initiated in 1993 and was intended to continue over a 15-year period to ascertain information in a number of areas of health, with the goal of incorporating study findings into interventions to enhance the health of postmenopausal women. WHI includes several randomized clinical trials as well as an observational cohort. Among these trials were studies involving the use of hormones, both unopposed estrogen and HRT, with the goal of the researchers to determine the effects of these hormones on risk for cardiovascular disease, osteoporosis, breast, and colorectal cancer. 4 The randomized hormone trials involved the assignment of women, who underwent hysterectomy, to conjugated equine estrogen (CEE) mg daily versus placebo and the randomization of women with an intact uterus to CEE combined with medroxyprogesterone acetate (MPA) 2.5 mg daily versus placebo. The overall WHI enrolled about postmenopausal women who were aged 50 to 79 years; the hormone program included predominantly healthy women, with about women in the estrogen versus placebo arm and in the estrogen/progestin versus placebo arm. ASiM: In April 2000, the Data Safety and Monitoring Board (DSMB) of WHI recommended that all women in the hormone program be informed of an increase in cardiovascular events. How did this affect continuation of the study? Dr Wenger: Based on review of the preliminary 2- year data, an unanticipated increase in cardiovascular events, including MI and stroke, was encountered in both hormone groups (conjugated equne estrogen [CEE] and conjugated equne estrogen plus medroxy progesterone acetate [CEE + MPA]) but not the placebo groups. These events were seen in about 1% of the women in the study and occurred in addition to the increased risk for venous thromboembolism (VTE) that had already been anticipated. The DSMB requested participants be notified because the excess of cardiovascular events was unanticipated and that aspect was not included in their informed consent document. With the potential for later benefit as the driving force behind continuing the studies, the DSMB recommended continuation. I would like to emphasize that the extent of the occurrence of cardiovascular events did not reach 710 Vol. 2, No. 20 October 2002
3 the preset stopping boundaries for the trial. The risk for these cardiovascular events persisted into years 3 and 4 of the study, but the trial was still continued based on DSMB recommendations. In May 2002, the DSMB identified that the increase in invasive breast cancer in the estrogen/progestin group exceeded the preset trial stopping boundaries, although this effect was not seen in women who were taking only estrogen. 5 The preset trial stopping boundaries were more stringent for the risk of breast cancer, an anticipated possible adverse event for the study, than they were for the beneficial effects that were anticipated in the trial for heart disease and stroke. Stopping boundaries in a clinical trial are designed to protect the participants in the study from further adverse events if they seem to be at risk by an intervention, which usually necessitates more stringent stopping rules. Benefit stopping grounds also exist for beneficial effects that should be extended to the general community, but more robust evidence often is required to terminate a trial for benefit. The findings at this point were significant: 26% increase in invasive breast cancer, 29% increase in CHD events, 41% increase in stroke, and a doubled risk for VTE. However, the same study also showed benefit: 37% decrease in colon cancer, 33% decrease in hip fracture, and 24% decrease in total fracture. The effect on allcause mortality was neutral. For overall scoring, risk exceeded benefit. ASiM: How can the practicing clinician apply the information from this study to the management of patients who are already taking combination HRT? Dr Wenger: While the absolute risk for an individual woman is very low, with over 97% of women in the study experiencing no adverse events, the population risk is substantial if this therapy is applied as a widespread primary prevention intervention. For example, if women were treated for 1 year with the CEE/MPA combination, the increase in events compared with placebo-treated women would be an additional 7 CHD events, 8 strokes, 8 pulmonary emboli, 18 VTE episodes, and 8 instances of invasive breast cancer. In contrast, the total number of colorectal cancers would decrease by 6, and hip fractures would decrease by 5. The risk-benefit ratio is inappropriate for a population-based primary prevention strategy, where the goal is to promote health and prevent disease. The estrogenonly arm did not show the increased risk for invasive breast cancer, so the estrogen-versus-placebo arm of the hormone study is continuing. Results of this study suggest that this particular estrogen/progestin combination should not be instituted or continued for the primary prevention of CHD. Decisions about continuation of HRT must be made on an individual basis, unrelated to CHD issues. ASiM: About the same time the WHI began, the Heart and Estrogen/Progestin Replacement Study (HERS) was recruiting patients. What were the goals of HERS, and how did the findings affect researchers recommendations? Dr Wenger: HERS was a landmark clinical trial designed to examine the effect of estrogen plus progestin on coronary risk in women with documented CHD. The study included 2763 menopausal women randomized to hormone therapy or placebo. The hormones and doses used were the same as those for the WHI HRT hormone arm: CEE mg plus MPA 2.5 mg daily. This combination was chosen, as was the case with WHI, because it was the preparation used by most US women on HRT. The results of this study, published in 1998, reported no difference between the hormone-treated and placebo-treated groups in the occurrence of nonfatal MI or coronary death, the primary trial outcome. 6 Furthermore, no benefit was seen for a variety of secondary cardiovascular outcomes, including coronary artery bypass graft surgery, percutaneous coronary revascularization, hospitalization for unstable angina or congestive heart failure, nonfatal ventricular arrhythmia, sudden death, stroke or transient ischemic attack, and peripheral arterial disease. 7 A 52% increase in risk for coronary events was noted during the first year, with a probable decreased risk in years 3 through 5. The risk for VTE increased 3-fold, and an increase of almost 50% was seen in incidence of gallbladder disease requiring surgery. 8 Thus, initiation of HRT was not recommended for the secondary prevention of CHD. However, at that time, researchers suggested that women already taking HRT might achieve late benefit. ASiM: If HERS showed no benefit for the secondary prevention of CHD overall, what is the significance of HERS II? Dr Wenger: HERS II was designed to determine whether the risk reduction in coronary events seen Advanced Studies in Medicine 711
4 during years 3 to 5 would persist with additional follow-up. HERS II included 93% of the surviving women from HERS (2321 individuals). This was an open-label study with women encouraged to remain on their original drug assignment; follow-up was by telephone contact only. The overall mean observation period was 6.8 years; in that time, no reduction in coronary events (MI or coronary death) or secondary cardiovascular events was seen in the HRT group compared with the placebo group for either HERS, HERS II, or for the total follow-up of almost 7 years. Even with adjustment for potential confounders and other factors such as statin use, the findings were not altered. Nor were they altered with analysis by an as-treated rather than an intention-to-treat basis. Other notable findings included a 2-fold increase in VTE and a nearly 50% increase in gallbladder disease requiring surgery in the hormone-treated group. Breast cancer, other cancers, hip fracture, or other fractures did not show any significant differences between the placebo and hormone-treated groups. ASiM: You suggest, based on the WHI results, that the combined hormone regimen should not be instituted or continued for the primary prevention of CHD. HERS and HERS II study participants already had CHD. How would you utilize the results of this study to advise postmenopausal women with CHD on the use of HRT? Dr Wenger: The HERS II findings, comparable to those from the WHI hormone study, indicate that menopausal hormone therapy should not be used to reduce the risk for cardiovascular events. This holds true for women who have CHD and are seeking secondary prevention as well as healthy women who are seeking primary prevention. The estrogen/progestin therapy does not provide CHD benefit and may actually increase risk. ASiM: Do you have any recommendations to offer the practicing clinician who treats postmenopausal women currently taking HRT? Dr Wenger: The ultimate decision rests with the patient, but only after careful discussion and consultation with her physician. This discussion should address the reasons for which menopausal hormone therapy was initiated and whether these reasons persist. Most commonly, therapy is initiated for menopausal symptoms. For these patients, the physician must ascertain whether therapy should be continued to relieve symptoms. If hormonal therapy was initiated for lipid lowering during the years when this was the recommended therapy, physicians should advise their patients that RISKS AND BENEFITS OF ESTROGEN PLUS PROGESTIN IN HEALTHY POSTMENOPAUSAL WOMEN Principal Results From the Women's Health Initiative Randomized Controlled Trial Writing Group for the Women's Health Initiative Investigators ABSTRACT Context: Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. Objective: To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. Design: Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which postmenopausal women aged years with an intact uterus at baseline were recruited by 40 US clinical centers in Interventions: Participants received conjugated equine estrogens, mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). Main Outcomes Measures: The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. Results: On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 ( ) with 286 cases; breast cancer, 1.26 ( ) with 290 cases; stroke, 1.41 ( ) with 212 cases; PE, 2.13 ( ) with 101 cases; colorectal cancer, 0.63 ( ) with 112 cases; endometrial cancer, 0.83 ( ) with 47 cases; hip fracture, 0.66 ( ) with 106 cases; and death due to other causes, 0.92 ( ) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 ( ) for total cardiovascular disease (arterial and venous disease), 1.03 ( ) for total cancer, 0.76 ( ) for combined fractures, 0.98 ( ) for total mortality, and 1.15 ( ) for the global index. Absolute excess risks per person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per personyears. Conclusions: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD. Reprinted with permission from JAMA. 2002;288(3): Vol. 2, No. 20 October 2002
5 the current recommendations for lipid lowering include statin use, as noted in the National Cholesterol Education Program Adult Treatment Panel III guidelines. 9 If hormone therapy was instituted because of low bone mineral density for the prevention of osteoporosis, the use of hormone therapy versus alternatives, such as bisphosphonates or raloxifene, and their specific risks and benefits, should be explored. Currently, no evidence supports that hormone therapy improves urinary inconti CARDIOVASCULAR DISEASE OUTCOMES DURING 6.8 YEARS OF HORMONE THERAPY Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) Deborah Grady, MD, MPH; David Herrington, MD, MHS; Vera Bittner, MD; Roger Blumenthal, MD; Michael Davidson, MD; Mark Hlatky, MD; Judith Hsia, MD; Stephen Hulley, MD, MPH; Alan Herd, MD; Steven Khan, MD; L. Kristin Newby, MD; David Waters, MD; Eric Vittinghoff, PhD; Nanette Wenger, MD; for the HERS Research Group ABSTRACT Context: The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among postmenopausal women with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5. Objective: To determine if the risk reduction observed in the later years of HERS persisted and resulted in an overall reduced risk of CHD events with additional years of follow-up. Design and Setting: Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent unblinded follow-up for 2.7 years (HERS II) conducted at outpatient and community settings at 20 US clinical centers. Participants: A total of 2763 postmenopausal women with CHD and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II. Intervention: Participants were randomly assigned to receive mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380), or placebo (n = 1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II. The proportions with at least 80% adherence to hormones declined from 81% (year 1) to 45% (year 6) in the hormone group, and increased from 0% (year 1) to 8% (year 6) in the placebo group. Main Outcome Measures: The primary outcome was nonfatal myocardial infarction and CHD death. Secondary cardiovascular events were coronary revascularization, hospitalization for unstable angina or congestive heart failure, nonfatal ventricular arrhythmia, sudden death, stroke or transient ischemic attack, and peripheral arterial disease. Results: There were no significant decreases in rates of primary CHD events or secondary cardiovascular events among women assigned to the hormone group compared with the placebo group in HERS, HERS II, or overall. The unadjusted relative hazard (RH) for CHD events in HERS was 0.99 (95% confidence interval [CI], ); HERS II, 1.00 (95% CI, ); and overall, 0.99 ( ). The overall RHs were similar after adjustment for potential confounders and differential use of statins between treatment groups (RH, 0.97; 95% CI, ), and in analyses restricted to women who were adherent to randomized treatment assignment (RH, 0.96; 95% CI, ). Conclusions: Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up. After 6.8 years, hormone therapy did not reduce risk of cardiovascular events in women with CHD. Postmenopausal hormone therapy should not be used to reduce risk for CHD events in women with CHD. Reprinted with permission from JAMA. 2002;288(1):49. nence, and it actually may cause this condition to worsen. I particularly want to emphasize that all of the information on which current decisions are being made were derived since 1998, the date of publication of the initial HERS study. Physicians and their patients must make decisions relative to 4 years of new and evolving information. ASiM: To date, have any additional notable new studies or publications other than the ones we have discussed shown harm or benefit from HRT? Dr Wenger: Until very recently, physicians have been dependent on information provided by a large number of observational studies and the meta-analyses of these studies that suggested cardiovascular benefit from HRT, which is why they had recommended hormone therapy for cardiovascular benefit in the past. In addition to the recent WHI and HERS II clinical trial data, newly published meta-analyses differ from the previous metaanalyses. One of these meta-analyses evaluates the value of HRT in the primary prevention of cardiovascular disease and coronary artery disease (CAD) by studying the potential explanatory variables of the relationship between HRT, CVD, and CAD. 10 This meta-analysis adjusted for socioeconomic status, as well as other major CAD risk factors, and shows that with these adjustments, no benefit in the secondary or primary prevention of CVD events is seen. This meta-analysis methods differ from traditionally cited studies, but most importantly, its results are consistent with those of the recent randomized trials that have shown no cardiovascular benefit from HRT. 5,8,10 Essentially, it highlights that differences previously described related to the characteristics of the women who were hormone users rather than to hormone use per se. Another recent meta-analysis produced comparable results. 11 We are dealing with a rapidly changing landscape. Good scientific information continues to emerge from rigorous, ongoing clinical trials. Thus, physicians should counsel women regarding hormone therapy based on the most current and appropriate scientific information. Advanced Studies in Medicine 713
6 REFERENCES 1. Centers for Disease Control and Prevention. Missed opportunities in preventive counseling for cardiovascular disease United States, MMWR Morb Mortal Wkly Rep.1998;47(5): Barrett-Connor E, Grady D, Sashegyi A, et al, for the MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [reprinted]. JAMA. 2002; 287(7): Wenger NK. Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women. Diabetes Obes Metab. 2002;4: Women s Health Initiative. New Facts About: ESTROGEN/ PROGESTIN HORMONE THERAPY. Available at: Accessed July 10, Writing Group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women s Health Initiative randomized controlled trial. JAMA. 2002; 228: Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998; 280: Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1): Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen Replacement Study follow-up (HERS II). JAMA. 2002; 288: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137(4): Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288: Vol. 2, No. 20 October 2002
Menopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationTHE WOMEN S HEALTH INITIAtive
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More informationFor more than 50 million American women, and millions
AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic
More informationHeart Disease in Women: Is it Really Different?
Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationHormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationThe view of The International Menopause Society on the Women s Health Initiative
CLIMACTERIC 2002;5:211 216 The view of The International Menopause Society on the Women s Health Initiative H. P. G., President of the International Menopause Society on behalf of the Executive Committee
More information9: 3 TABLE OF CONTENTS P&T
Vol 9: No 3 TABLE OF CONTENTS Short-term Safety of Antipsychotics for Dementia 1-2 Preoperative Statins and Effects on Mortality 2-4 Hormone Replacement Therapy and Risk of Venous Thromboembolism 4-5 P&T
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationTHE SAFETY CHECK LIST BEFORE STARTING HT
THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationOVERVIEW WOMEN S HEALTH: YEAR IN REVIEW
OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationMenopausal Hormone Therapy
V FORUM on WOMEN, HEALTH, and GENDER Madrid, October 14-15, 2008 Menopausal Hormone Therapy The Women s Health Initiative (WHI) randomized, placebo-controlled trials Marcia L. Stefanick, Ph.D. Professor
More informationAspirin for the Prevention of Cardiovascular Disease
Detail-Document #250601 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2009 ~ Volume 25 ~ Number 250601 Aspirin for the Prevention of Cardiovascular
More informationEvidence Synthesis Number 93
Evidence Synthesis Number 93 Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationCoronary heart disease (CHD) is the single leading cause of
AHA/ACC Scientific Statement: Consensus Panel Statement Guide to Preventive Cardiology for Women Lori Mosca, MD, PhD, Chair; Scott M. Grundy, MD, PhD; Debra Judelson, MD; Kathleen King, PhD, RN; Marian
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationHormone replacement therapy in postmenopausal women
The American Journal of Surgery 188 (2004) 136 149 Review Hormone replacement therapy in postmenopausal women Edgar D. Staren, M.D., Ph.D., M.B.A.*, Shuab Omer, M.D. Department of Surgery, Medical College
More informationHormone therapy (HT) is one ABSTRACT WOMEN S HEALTH. Current Status of Postmenopausal Hormone Therapy. Mary S. Beattie, MD
Current Status of Postmenopausal Hormone Therapy Mary S. Beattie, MD ABSTRACT Estrogen therapy, with or without progestins, has been widely prescribed for the treatment of menopausal symptoms. However,
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationCORONARY HEART DISEASE
ORIGINAL CONTRIBUTION Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial Elizabeth Barrett-Connor,
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationBenefit/Risk Assessment A Critical Need
Benefit/Risk Assessment A Critical Need Christy Chuang-Stein, PhD Statistics, Pfizer Inc Society for Clinical Trials 30 th Annual Meeting 1 Some Basic Facts All pharmaceutical products have side effects
More informationMenopausal hormone therapy includes various forms, Review
Review Annals of Internal Medicine Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Heidi
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationPRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome
CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationProblems in Postmenopausal Women
Menopausal Management: Where are we in 27? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationThe Women s Health Initiative: Lessons Learned
Annu. Rev. Public Health 2007. 29:131 50 The Annual Review of Public Health is online at http://publhealth.annualreviews.org This article s doi: 10.1146/annurev.publhealth.29.020907.090947 Copyright c
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Carole S. Ben-Maimon, M.D. President and Chief Operating Officer One
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationAnnals of Internal Medicine
2 May 2000 Volume 132 Number 9 Annals of Internal Medicine Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease The Heart and Estrogen/progestin Replacement Study Deborah Grady,
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationCOMPARED WITH PLACEBO,
IGINAL INVESTIGATION Esterified Estrogen and Conjugated Equine Estrogen and the Risk of Incident Myocardial Infarction and Stroke Rozenn N. Lemaitre, PhD, MPH; Noel S. Weiss, MD, DrPH; Nicholas L. Smith,
More informationRALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?
Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA 16917 GUIDELINES FOR USE 1. Is the request for the prevention (risk reduction) of breast cancer? If yes, continue to #2. If no, approve by HICL
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationAPPROXIMATELY 38% OF POSTmenopausal
SCIENTIFIC REVIEW AND CLINICAL APPLICATIONS CLINICIAN S CORNER Postmenopausal Hormone Replacement Therapy Scientific Review Heidi D. Nelson, MD, MPH Linda L. Humphrey, MD, MPH Peggy Nygren, MA Steven M.
More informationCoronary Heart Disease in Women: Is There Any Role for Menopausal Hormone Therapy in Cardiac Protection?
N ovember 24 V olume 8, Issue 9 www.cardiologyrounds.org Coronary Heart Disease in Women: Is There Any Role for Menopausal Hormone Therapy in Cardiac Protection? BY NANETTE K. WENGER, MD, FACC, FAHA, MACP
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationTrial: Take-Home Message: Executive Summary: Guidelines:
Trial: Davies C, et al. "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial".
More informationCLINICAL TRIALS: THE BASICS
CLINICAL TRIALS: THE BASICS MARTA HAYDEN, MSN, RN, OCN CANCER RESEARCH MANAGER FOR NCI CLINICAL TRIALS HELEN F. GRAHAM CANCER CENTER & RESEARCH INSTITUTE DEDICATION This talk is dedicated to the researchers
More informationStatus Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More information